Navigation Links
Targeted drug therapy prevents exercise-induced arrhythmias
Date:3/29/2009

de calcium-handling proteins, the ryanodine receptor and calsequestrin, cause the disorder.

In 2006, the group discovered how these mutations cause arrhythmias at the cellular level by allowing calcium to "leak" out of its storage containers inside heart cells. Knollmann's team developed a mouse model for CPVT (by eliminating the calsequestrin gene) and proposed using the model to study medications and interventions for the disorder.

They tried flecainide, a clinically available anti-arrhythmic that is used to treat atrial fibrillation. It worked.

In isolated heart cells, flecainide blocked the ryanodine receptor and the calcium "leak" (the underlying molecular defect in CPVT), and it completely prevented ventricular arrhythmias in the mouse model of CPVT.

"So we knew that this established drug specifically targets the disease mechanism in CPVT," Knollmann said.

With these encouraging results, the investigators teamed with Arthur Wilde, M.D., Ph.D., at the University of Amsterdam, to test flecainide in two patients with CPVT who continued to have arrhythmias while on conventional therapies the previously mentioned 12-year-old boy and a 36-year-old woman. The boy has a mutation in the calsequestrin gene, the same gene mutated in the mouse model; the woman has a mutation in the ryanodine receptor, which is more common among CPVT patients.

In both patients, flecainide (combined with a beta blocker in the boy) prevented exercise-induced ventricular arrhythmias. The patients have taken flecainide for more than six months now and are living normal lives.

The group is currently enrolling additional CPVT patients to clearly define the benefits and risks of flecainide and to compare how it works in patients who have varying ryanodine receptor and calsequestrin mutations.

Frank Fish, M.D., a pediatric cardiologist at Vanderbilt, has placed two patients with CPVT on flecainide therapy.

"We're hoping that
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Bethesda, MDA combination of two techniques promises to ... while also reducing potential side effects says a new ... the FASEB Journal ( http://www.fasebj.org ). The ... involving the use of site-specific recombinases, or enzymes that ...
... and climatic zones move polewards, species will need to find ... the journal Molecular Ecology , has revealed that climate ... a range of new habitats. The study, led ... to understand the role of evolution in helping a species ...
... looks like bone. It feels like bone. For the most ... inkjet printer., Washington State University researchers have used a 3D ... be used in orthopedic procedures, dental work, and to deliver ... as a scaffold for new bone to grow on and ...
Cached Biology News:The newest of the new in gene therapy: 'Tag and target and exchange' 2British butterfly is evolving to respond to climate change 2
(Date:5/1/2015)... 2015 According to a ... (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by Technology ... Institutes) - Analysis & Global Forecast to 2019", ... Antibody Production Market for the forecast period of ... reach $2.572 Billion by 2019 from $1.425 Billion ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has commenced an underwritten public offering of its ... underwriters a 30-day option to purchase up to an ... offered in the public offering. The offering is subject ... as to whether or when the offering may be ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... PETERSBURG, Va., Jan. 6 Star Scientific (Nasdaq ... Pharmaceuticals, Inc., in conjunction with its Star Tobacco, ... the ability of Stonewall(R) dissolvable smokeless tobacco ... an over-the-counter nicotine replacement product (NRT). The study, ...
... Inc., a leading provider,of software and high quality ... analysis , today announced that Bayer Schering Pharma ... years. Bayer Schering Pharma,has programs for cancer, ... coverage of these diseases and others. GeneGo ...
... Way For Use of ALD Ultra High-k Insulators; Marks ... ST. LOUIS, Jan. 6 ASM International N.V. (Nasdaq: ... and SAFC Hitech(TM), a business segment within SAFC(R), a ... ), today announced that they have entered into a ...
Cached Biology Technology:Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years 2ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 2ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 3ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement 4
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
... raised against a partial recombinant ... K6HF (NP_004684, 141 a.a. ... protein with GST tag. ... NM_004693 Protein ...
... DNA Visualizer DX's sensitivity of DNA detection ... DNA band in an agarose gel can be ... this kit can be purified by organic solvent ... tested commercially kits worked well.) DNA excised ...
Biology Products: